Ascent Group LLC increased its position in Eli Lilly and Company by purchasing an additional 575 shares during the third quarter, bringing its total holding to 17,821 shares valued at $13.598 million according to the latest SEC 13F filing. Vanguard Group Inc. also raised its stake by 1.5%, adding 1,183,038 shares to hold 80,407,430 shares worth approximately $62.68 billion. Laurel Wealth Advisors LLC executed a dramatic increase of 78,621.2%, ending the period with 11,552,336 shares valued at $9.005 billion, while Norges Bank initiated a new position worth about $8.828 billion. Jennison Associates LLC and AllianceBernstein L.P. further boosted their exposures by 4.3% and 7.9%, respectively, with Jennison acquiring 226,620 additional shares and AllianceBernstein buying 397,696 shares during the same period. Combined, institutional investors and hedge funds now own 82.53% of the company’s outstanding shares.

For the third quarter, Eli Lilly reported earnings per share of $7.02, outperforming the consensus estimate of $6.42, on revenue of $17.60 billion versus expectations of $16.09 billion, reflecting year‐over‐year revenue growth of 53.9%. Net margin stood at 30.99% and return on equity was 109.52%. Management reaffirmed full-year earnings guidance in the range of $23.00–$23.70 per share. In November, the company announced a quarterly dividend of $1.73 per share, to be paid in March, representing an annualized dividend yield of approximately 0.6% and a payout ratio of 29.35%, supported by robust cash flow generation.

Equity research analysts maintain a bullish stance, with four assigning a Strong Buy rating, seventeen a Buy rating and five a Hold rating, resulting in an overall consensus rating of Moderate Buy. Price targets have been revised upward in recent months, with the consensus target now at $1,155.36 per share, reflecting expectations for multiple expansion should the company’s pipeline catalysts in oncology and metabolic disease deliver positive trial data.

Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly and Company is a global pharmaceutical leader researching, developing and commercializing medicines across oncology, immunology, neuroscience and metabolic disease. The company operates in North America, Europe, Asia and emerging markets, pursuing growth through strategic acquisitions, licensing agreements and a diversified pipeline of over 60 oncology programs alongside late‐stage assets in diabetes and obesity management.